Arrowhead Research | ARWR - Operating Expenses


Arrowhead Research reported $215M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Ligand Pharmaceuticals USD 34.35M 5.27M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Moderna USD 1.78B 242M Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.29B 507M Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
TG Therapeutics USD 170.12M 28.04M Mar/2026
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026
Xencor USD 82.38M 513K Mar/2026